Clinical characteristics | Low GRACE score group (n=229) | Intermediate-high GRACE score group (n=112) | P value |
Age (years), mean±SD | 57.4±9.1 | 68.3±8.7 | <0.001 |
Gender, (%) | |||
Male | 135 (59.0) | 65 (58.0) | 0.907 |
Time from symptoms onset to fibrinolytic therapy, median (hours) (IQR: 25th, 75th percentile) | 2.8 (IQR: 2,4.0) | 2.9 (IQR: 2,4.6) | 0.571 |
Time from fibrinolysis to coronary intervention, median (days) (IQR: 25th, 75th percentile) | 5.5 (IQR:2.9,9.1) | 6.2 (IQR: 3.1,10.3) | 0.625 |
LVEF (%) | 54.5±11.1 | 53.1±12.9 | 0.306 |
GRACE score, mean±SD | 100.1±17.7 | 142.2±14.3 | <0.001 |
Medical conditions, n (%) | |||
Smoking | 145 (63.8) | 62 (55.4) | 0.151 |
Hypertension | 103 (45.0) | 57 (50.9) | 0.355 |
Diabetes | 48 (20.9) | 17 (15.2) | 0.241 |
Dyslipidaemia | 104 (45.8) | 32 (28.6) | 0.002 |
Smoking | 145 (63.8) | 62 (55.4) | 0.155 |
Chronic kidney disease | 11 (4.8) | 10 (9.0) | 0.151 |
Prior PCI | 2 (0.9) | 6 (5.4) | 0.017 |
Medications, n (%) | |||
Aspirin | 229 (100) | 112 (100) | NA |
Clopidogrel | 220 (96.1) | 107 (95.5) | 0.779 |
Low molecular weight heparin | 209 (91.7) | 103 (92.0) | 0.554 |
ACEI/ARB | 167 (72.9) | 88 (78.6) | 0.260 |
Beta-blocker | 144 (62.8) | 72 (64.2) | 0.801 |
Data presented as n (%) or mean±SD or median (IQR).
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; GRACE, Global Registry for Acute Coronary Events; LVEF, left ventricular ejection fraction; NA, not applicable; PCI, percutaneous coronary intervention.